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A B S T R A C T
Pulmonary Arterial Hypertension (PAH) is a rare and devasting condition characterized by elevated
pulmonary vascular resistance and pulmonary artery pressure leading to right-heart failure and
premature death.
Pathologic alterations in proliferation, migration and survival of all cell types composing the vascular
tissue play a key role in the occlusion of the vascular lumen. In the current study, we initially investigated
the action of selective class I and class II HDAC inhibitors on the proliferation and migration of pulmonary
artery smooth muscle cells (PASMCs) after exposure to Platelet Derived Growth Factor (PDGF). Class I
HDAC inhibitors were able to counteract the hyperproliferative response to PDGF, reducing both
proliferation and migration in PASMCs, while class II were ineffective. Selective silencing with siRNAs
targeted against different HDACs revealed a major role of class I, and within this class, of HDAC1 in
mediating PDGF-induced Akt Phosphorylation and Cyclin D1 (CycD1) expression. These results from
these combinatorial approaches were further conﬁrmed by the ability of a speciﬁc HDAC1 inhibitor to
antagonize the PDGF action. The ﬁnding that HDAC1 is a major conductor of PDGF-induced patterning in
PAH-PASMCs prompts the development of novel selective inhibitors of this member of class I HDACs as a
potential tool to control lung vascular homeostasis in PAH.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Pulmonary Arterial Hypertension (PAH) is a rare and multi-
factorial condition characterized by elevated pulmonary vascular
resistance and pulmonary artery pressure leading to right-heart
failure and premature death [1,2].
The progressive increase of pressure load is due to a dramatic
pulmonary arterial wall remodeling involving all cellular compo-
nents of the vessel. Dysfunction in cell proliferation, migration,* Corresponding author at: Laboratory of Experimental Cardiology, Pav.21 DIMES
University of Bologna, Via Massarenti 9, 40138 Bologna, Italy.
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0006-2952/ 2014 The Authors. Published by Elsevier Inc. This is an open access article unsurvival, inﬂammation and thrombosis lead to a thickening of the
vascular walls and to a subsequent occlusion of the lumen [3].
Within many factors involved in these processes, platelet derived
growth factor (PDGF) pathway plays a pivotal role in modulating
Pulmonary Artery Smooth Muscle Cells (PASMCs) proliferation and
migration [4,5].
Current treatments are only able to slow down the progression
of PAH thus a real cure does not exist [6]. Furthermore, the
mechanisms underlying the onset and progression of PAH have not
been fully elucidated yet. For these reasons studies addressing the
etiology of the disease and directed to identify new therapeutic
targets are needed.
Histone Deacetylases (HDACs) remove the acetyl group from
the amino termini of Lysine residues of histones and other various
substrates including transcription factors, chaperones, as well asder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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metabolism [7]. Within 18 mammalian family members the 11
known zinc-dependent HDACs are classiﬁed into 4 subgroups:
class I (HDAC 1, 2, 3, 8), class IIa (HDAC 4, 5, 7, 9), class IIb (HDAC 6,
10) and class IV (HDAC 11) [8,9].
These enzymes are involved in many different biological and
pathological processes: their role in cancer progression has long
been established since 1998 [10] but these molecules have been
associated also with Pulmonary Arterial Hypertension [11],
diabetes [12], memory formation [13], Parkinson disease [14]
and inﬂammation processes in Rheumatoid Arthritis [15]. Histone
Deacetylase inhibitors (HDACis) have been developed to counter-
act the proliferation of cancer cells and showed promising results
by inducing cell cycle arrest, apoptosis and anti-angiogenic effects
[16]. Pan-HDACis also reduce cardiac hypertrophy in PAH rats and
inhibit the ‘‘highly proliferative phenotype’’ of PDGF-treated
vascular cells [11]; selective class I HDACis counteract hypoxia-
induced cardiopulmonary remodeling in rats [17] and class II
HDACis are involved in blocking the fetal gene reactivation in
heart, reducing hypertrophy [18]. Among different classes,
however, it is still not clear which speciﬁc HDAC is involved in
promoting these pathological processes. In PAH abnormalities are
found in both heart and lung cells. The need for ‘‘more’’ speciﬁc
targets also arises from the fact that different HDACs among their
class I have been reported to have distinct functions in heart and
lungs: it is known indeed that the inhibition of class I HDAC
reduces cardiopulmonary vessel remodeling, but the knockout of
HDAC3 (belonging to class I) induces a hypertrophic phenotype in
hearts [19].
We previously provide evidence that a pan-inhibitor of HDACs,
Sodium Butyrate (NaBU), reduced the proliferation and migration
induced by PDGF in PASMCs isolated from rats with monocrotaline
(MCT)-induced PAH [20].
In the current study, we aimed at further dissecting the role of
HDACs in these cells, and attempted to establish whether the
proliferative/migratory action of PDGF may be executed through
the intervention of multiple classes of HDACs, including class I and
II, or it may conversely involve a single HDAC class, and in the
afﬁrmative, a targeted class member. For this purpose, we used a
combinatorial approach encompassing the use of two novel
hydroxamate derivatives MC1855 [21] and MC1575 [8], displaying
speciﬁc inhibitory action toward class I and II HDACs, respectively,
as well as the use of a speciﬁc inhibitor of class I HADC1. With this
strategy, and by the aid of siRNAs speciﬁcally directed against each
member of class I HDAC, we provide evidence that the PDGF effects
on PAH PASMCs were primarily elicited through the activity of
class I HDAC1.
2. Methods
2.1. Ethics statement
Animal use was approved by the Bioethics Committee of the
University of Bologna, in compliance with Directive 2010/63/EU of
the European Parliament. The study was conducted adhering to the
institutions guidelines for animal husbandry regarding food space
light temperature (23–25 8C).
2.2. Cell isolation and culture conditions
Adult male Sprague-Dawley rats (200–250 g in body weight;
Harlan Laboratories; Indianapolis, IN, USA) were subjected to a
subcutaneous injection of 60 mg/kg of MCT (Sigma–Aldrich; St.
Louis, MO, USA) [20]. After 28 days, all rats were anesthetized in a
CO2/O2 mixture and subsequently killed by cervical dislocation.
Intrapulmonary arteries were isolated and cleaned of connectivetissue. The isolation of PASMCs, from PAH-animals, has been
performed using a modiﬁcation of previously described method
[22]. The tissue was digested at 37 8C for 20 min in DMEM
containing collagenase type I, 250 U/ml (Sigma–Aldrich; St. Louis,
MO, USA). Fetal Bovine Serum (FBS) 10% was added to stop the
reaction and the digested pieces were placed into petri dish
containing fresh complete medium. After reaching conﬂuence cells
were frozen. PASMCs were cultured in DMEM with 10% FBS, 100 U/
ml penicillin and 100 mg/ml streptomycin, 4 mM L-glutamine (all
reagents from LONZA; Basel, Switzerland). PASMCs from the third
to the fourth passages were used for all studies. To induce cell cycle
synchronization a serum starvation was performed culturing cells
at low percentage of serum (0.5% FBS) for 24 h. PASMCs were
induced to proliferate and migrate by replacing starvation medium
with fresh low serum medium containing 20 ng/ml PDGF
(PeProtech; Rocky Hill, NJ, USA). MC1855 and MC1575 were
synthesized in our laboratories at Sapienza University of Rome
(Rome, Italy) as previously described [23], dissolved in DMSO and
stored at 20 8C before use. NaBU and 4-(dimethylamino)-N-[6-
(hydroxy amino)-6-oxohexyl]-benzamide (HDAC1-I) were pur-
chased from Sigma–Aldrich (St. Louis, MO, USA) and Santa Cruz Inc.
(Santa Cruz, CA, USA), respectively. The HDACis were added at the
indicated concentrations concurrently with the PDGF, while the
phosphatase inhibitor Calyculin A (CA), (Sigma–Aldrich; St. Louis,
MO, USA), were administered 1 mM 1 h before the treatment. All
experiments were repeated at least ﬁve times, unless otherwise
mentioned.
2.3. MTT assay
PASMCs were seeded 3000 cells/cm2 in 48-well plates and
starved for 24 h. After 24 h of treatment MTT assay (Sigma–
Aldrich; St. Louis, MO, USA) was performed to test cell growth.
Cells were then incubated with MTT (20 ml/well of 5 mg/ml 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide in phos-
phate buffered saline [PBS]) for 3 h and lysed with the same
volume of lysis buffer (10% SDS 10 mM NaOH), the absorbance was
measured at 570 nm with a spectrophotometric plate reader.
2.4. Measurement of cell migration in vitro
Cells were seeded (15,000 cells/well in 24-well plates), starved
for 24 h and cultured with treating medium for additional 16 h. The
conﬂuent cell monolayer was scraped with a pipette tip across the
diameter of the well. After removal of cell debris by washing with
PBS two times, cells were observed for 6 h. The wound area at the
beginning of wounding and at the end of treatment was
photographed respectively under an inverted phase-contrast
microscope equipped with digital sight camera (Nikon; Tokio,
Japan). The recovered surface area was calculated by subtracting
the wound area at the end of treatment from the corresponding
original wound area.
2.5. Immunoﬂuorescence
Cycling cells expressing ki67 protein were identiﬁed using a
single immunoﬂuorescence staining. PASMCs were seeded on glass
slides into 12-well plates at a density of 3000 cells/cm2, starved
and treated with the appropriate molecules in low-serum medium.
After 24 h, cells were washed, ﬁxed in 2% paraformaldehyde in PBS
for 4 min at room temperature (RT) and permeabilized with 0.5%
Tryton X-100 for 10 min After washes, the slides were treated with
1% bovine serum albumin (BSA), (Sigma–Aldrich; St. Louis, MO,
USA) in PBS solution for 30 min at RT in a wet chamber to reduce
non-speciﬁc staining and stained for 1 h at 37 8C with monoclonal
antibody anti-ki67 (1:100, Novocastra, Leica Microsystems;
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AlexaFluor-488 (1:250, Life Technology; Carlsbad, CA, USA)
secondary antibody for 1 h at 37 8C in the dark. Both antibodies
were diluted in 1% BSA in PBS. Samples were counterstained with
Pro Long anti-fade reagent with DAPI (Molecular Probes, Thermo
Fisher Scientiﬁc; Waltham, MA, USA) and observed in a Leica
DMI6000 B inverted ﬂuorescence microscope (Leica Microsys-
tems; Wetzlar, Germany); all images were taken at 10
magniﬁcation. For negative control, samples were processed
omitting the primary antibody.
2.6. AgNOR
Proteins associated with the nucleolar organizer regions were
evaluated with AgNOR staining as previously described [24].
PASMCs seeded on glass slides were ﬁxed with 2% paraformalde-
hyde in PBS plus 1% Triton X-100 for 10 min at RT. After washings,
samples were stained with a solution containing one volume of 2%
gelatin in 1% aqueous formic acid and two volumes of 50% silver
nitrate for 10 min at 37 8C in the dark. Finally, PASMCs were
dehydrated and mounted without nuclear contrast. Images were
taken at 40 magniﬁcation through a video camera (JVC 3CCD
video camera, KY-F55B) connected with a Leitz Diaplan light
microscope; AgNOR analysis and quantiﬁcation was carried out
with Image-Pro Plus (Media Cybernetics, www.mediacy.com).
AgNOR staining was measured in a minimum of 100 nuclei at 40
magniﬁcation; results were expressed as mean nucleolus (na)/
nucleus (Na) ratio normalized to control.
2.7. Tunel assay
DNA fragmentation was evaluated with TUNEL (Terminal
deoxynucleotidyl transferase-mediated dUTP Nick End-Labeling)
assay using the ‘‘In situ cell death detection kit, POD’’ (Roche; Basel,
Switzerland) following the manufacturer’s instructions. Three mm-
thick sections from formalin-ﬁxed, parafﬁn-embedded PASMC
pellets were dewaxed and rehydrated. Endogenous peroxidase was
blocked by incubation in 3% H2O2 in methanol for 10 min at RT in
the dark and antigenicity was recovered treating the samples withFig. 1. Effect of MC1855 (class I speciﬁc HDACi) and MC1575 (class II speciﬁc HDACi) on
MC1855 or MC1575 on PDGF-induced proliferation as evaluated by MTT assay after 24 h 
of different doses of MC1855 or MC1575 on PDGF-induced migration extent, measured
images from wound healing test (5 mM MC1855 and 5 mM MC1575). Dotted lines com
expressed as mean  sem and represent data averaged from 5 independent experimentsProteinase K (DakoCytomation; Carpinteria, CA, USA) for 30 min at
37 8C. After washing, slides were treated with 50 ml of TUNEL
reaction mixture (enzyme solution, diluted 1:5 in TUNEL Dilution
Buffer and Label Solution) for 1 h a 37 8C in the dark. After that,
sections were washed, incubated with Converted POD, revealed
with DAB (3,30-diaminobenzidine) (Sigma–Aldrich; St. Louis, MO,
USA), counterstained with hematoxylin and mounted in a
synthetic medium. As positive controls sections were treated with
DNase I for 10 min at RT before exposure to TUNEL reaction
mixture. Negative controls were obtained by omitting enzyme
solution.
2.8. Pulmonary artery ring assay
Forty-eight-well plate were covered with Basement Membrane
Extract (BME) (Trevigen; Gaithersburg, MD, USA) 100 ml/well and
incubated for 30 min at 37 8C with 5% CO2 to form semisolid
medium. After sacriﬁce of rats intrapulmonary arteries were
isolated, cleaned of ﬁbroadipose tissue and cut into 1–1.5 mm long
cross sections. Sections were rinsed ﬁve times using 0.5% FBS
culture medium containing PDGF with or without HDACis and
placed in 100 ml BME-coated 48-wells, then covered with an
additional 100 ml of BME. During the experiment medium was
replaced every three days.
2.9. Protein isolation, Western blotting
PASMCs monolayers were lysed in radioimmune precipitation
assay buffer (RIPA) (Pierce; Thermo Fisher Scientiﬁc; Waltham,
MA, USA). Protein content was determined using Bradford
colorimetric protein assay (Sigma–Aldrich; St. Louis, MO, USA)
following manufacturer’s instructions. 30 mg of proteins were
separated using 8–12% SDS-PAGE and transferred to a polyvinyli-
dene diﬂuoride membrane (Sigma–Aldrich; St. Louis, MO, USA).
The ﬁlters were hybridized with the appropriate primary
antibodies followed by a horseradish peroxidase-conjugated
secondary antibody. The bands were visualized using the ECL
method (Thermo Fisher Scientiﬁc; Waltham, MA, USA) and
quantiﬁed using Molecular Imager1 ChemiDocTM XRS+ with PDGF-induced PASMCs proliferation and migration. (A) Effect of different doses of
of treatment. Time 0 (white lane) are also shown as a proliferation control. (B) Effect
 as the difference in cells covered area after 6 h of observation. (C) Representative
prise cell covered area before the observation start. The quantitative results are
*p < 0.05; **p < 0.01; ***p < 0.005 vs PDGF-treated group.
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USA). An anti-Vinculin antibody (1:5000, Sigma–Aldrich; St. Louis,
MO, USA) was used as the loading control. The following antibodies
were used: anti-Phospho Akt (Ser473) and anti-Akt (1:1000, Cell
Signaling; Danvers, MA, USA), anti-CycD1 (1:1000, BD).
2.10. Quantitative RT-PCR
RNeasy Micro Kit (Qiagen) was utilized for RNA isolation from
PASMCs. The cDNA was synthesized in a 20-ml reaction starting
from 1 mg of total RNA with SuperScript III RT (Life Technologies;
Thermo Fisher Scientiﬁc; Waltham, MA, USA). Quantitative RT-PCR
was performed using the LightCyclerSYBR Green fast start kit
(Lightcycler1 FastStart DNA MasterPLUS SYBR Green I). The
following Qiagen QuantiTect primers were used for real-time
RT-PCR: ccnd1, hdac1, hdac2, hdac3, hdac8. Data were normalized
using gapdh and actin b (actb) both from Qiagen (Hilden,Fig. 2. Effect of 5 mM MC1855 (class I speciﬁc HDACi), 5 mM MC1575 (class II speciﬁ
pulmonary artery rings from MCT-treated rats. Representative images of pulmonary arGermany). For each primer a melting curve analysis was performed
and real-time PCR efﬁciency was calculated. Results were analyzed
and related plots were created using Relative Expression Software
Tool (REST 2009 V2.0.13, Qiagen).
2.11. SiRNA transfection
The day before transfection, cells were seeded at the
concentration of 10,000 cells/cm2 into 6-well plates. LIPOFECTA-
MINE 2000 (Life Technology; Carlsbad, CA, USA) was used to
transfect 10 nM siRNAs into the cells following manufacturer’s
instructions. The following siRNAs were used: rat HDAC1 HDAC2,
HDAC3, HDAC8 iBONI siRNA pool were purchased from Riboxx
(Dresden, Germany). After 24 h cells were starved, then treated for
Western blotting analysis. Each HDAC level was evaluated by
quantitative real-time PCR 48 h after the transfection in untreated
starved cells.c HDACi) and 5 mM NaBU (non-selective HDACi) on PDGF-induced sprouting in
tery before and after 10 days of treatment.
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All values are expressed as the mean  SEM. Data were
statistically analyzed using one way ANOVA followed by appropriate
post hoc test. All experiments were repeated at least ﬁve times, unless
otherwise mentioned. A value for p  0.05 was considered to be
statistically signiﬁcant.
3. Results
3.1. Class I, but not class II HDAC inhibitors counteract PDGF induced
proliferation and migration of PASMCs from PAH-rats
We previously tested the ability of PDGF in inducing the
proliferation of PASMCs isolated from rats with experimentally
induced PAH and we demonstrated that NaBU, a broad-spectrum
HDACi, counteracted the PDGF effect [20].
Here we show that increasing concentrations of a selective class
I HDACi, MC1855 (ranging from 1 to 20 mM) signiﬁcantly inhibited
PASMC proliferation as revealed by MTT analysis after 24 h. On the
contrary, the class II HDACi, MC1575, counteracted PDGF
signiﬁcantly only at the higher concentration (20 mM) (Fig. 1A).
Similar results were obtained when the effect of HDAC class
selective inhibitors on PASMC migration was investigated using a
wound healing assay. After 16 h of PDGF stimulation with or
without HDACi treatment a wound was performed on the cells
layer and the migration area was calculated after 6 h to exclude
any confounding effect due to proliferation process. Remarkably,
MC1855 dose-dependently inhibited the PDGF-induced migrationFig. 3. Effect of MC1855 (class I speciﬁc HDACi) and MC1575 (class II speciﬁc HDACi) on Ak
PASMCs after a treatment up to 24 h long with PDGF with or without 5 mM MC1855, 5 m
control (ctrl). Representative images of 5 different experiments. (B) Transcriptional level o
MC1575 or 5 mM NaBU. Real-time PCR data, normalized to gapdh and actin beta housek
PDGF alone. Statistical analysis of 5 different experiments was analyzed using REST 200
without MC1855 and/or phosphatase inhibitor Calyculin A (CA). Cells were pretreated wi
Representative image of 4 different experiments. (D) Protein level after 7 h PDGF-treatm
with CA for 1 h before adding PDGF and HDACi. Untreated cells were used as a controwhereas MC1575 did not affect the stimulatory effect of the
growth factor even at the highest concentration (Fig. 1B and C).
To conﬁrm the inhibitory effect of MC1855 on PDGF-induced
migration, we performed pulmonary artery ring assay. Starting
from 6 days of treatment and throughout a period of 12 days, PDGF
induced sprouting in pulmonary artery rings from PAH-rats.
MC1855, but not MC1575, was able to mitigate this effect, in an
extent comparable to that achieved using the broad-spectrum
HDACi, NaBU (Fig. 2).
3.2. MC1855, but not MC1575 down-regulate Cyclin D1 gene
expression and accelerated Akt de-phosphorylation
In order to provide deeper insights into the molecular
mechanisms of MC1855 we analyzed the Akt phosphorylation
on Ser473. PDGF treatment was able to fully activate the Akt in
PAH-Rat PASMCs. After 7 h, 5 mM MC1855 retraced the action of
NaBU in decreasing Akt phosphorylation induced by a single PDGF
administration (Fig. 3A). Interestingly, the inhibition of class II
HDACs did not affect the phosphorylation state of Akt during the 24
h-treatment.
We next analyzed the activation of CycD1 one of the
downstream components of PDGF signaling [25,26]. Gene expres-
sion of CycD1 was reduced in presence of MC1855 and NaBU but
not with MC1575 (Fig. 3B), suggesting that class I HDACi are also
able to act on the regulation on the CycD1.
Given the antiproliferative and antimigratory effects of
MC1855, we decided to focus only on this molecule exclusively
to establish possible mechanisms that class I HDACi may have on
PAH cell proliferation and migration.t phosphorylation and CycD1 expression. (A) Phosphorylation state of Ser473-Akt in
M MC1575 or 5 mM NaBU (pan-inhibitor of HDACs). Untreated cells were used as a
f CycD1 in PASMC after 7 h of PDGF-treatment with or without 5 mM MC1855, 5 mM
eeping genes, were expressed as relative fold change of PDGF + HDACi compared to
9 software (QIAGEN): *p < 0.05. (C) Protein level after 7 h PDGF-treatment with or
th CA for 1 h before adding PDGF and HDACi. Untreated cells were used as a control.
ent with or without NaBU and/or phosphatase inhibitor CA. Cells were pretreated
l. Representative image of 3 different experiments.
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phosphatases
We recently demonstrated that NaBU exerts its role on Akt
phosphorylation acting on a phosphatase that is sensitive to
phosphatase inhibitor Calyculin A (CA) after 7 h of treatment in
presence of PDGF [20]. Interestingly, both MC1855 (Fig. 3C) and
NaBU (Fig. 3D) blunted the CycD1 protein expression induced by
PDGF, whereas the CA administration was able to restore CycD1
protein level (Fig. 3C and D).Fig. 4. Effect of separate class I HDACs knockdowns on Akt phosphorylation and CycD1 ex
exposure to HDAC speciﬁc siRNAs. Fold changes compared to the scramble control wer
speciﬁc small interfering RNAs (siRNAs) on PDGF induced Ser473-phosphorylation of Akt an
internal loading controls respectively of Akt phosphorylation and CycD1 level. Representati
densitometric analysis of Western blot experiments. Results were expressed as phospho/tot
protein level was shown as mean  sem; *p < 0.05. (D) Effect on CycD1 level as assessed by a
Vinculin level change compared to that of the scramble control. Relative protein level quan
HDAC1 or HDAC2 on PDGF-induced proliferation as evaluated by MTT assay after 24 h o
*p < 0.05. (F) Effect of siRNA against HDAC1 or HDAC2 on PDGF-induced migration extent, me
the scramble + PDGF were expressed as mean  sem; *p < 0.05.3.4. HDAC1 is the key of MC1855 effect on Akt phosphorylation and
Cyclin D1 expression
To identify the contribution on Akt phosphorylation of different
HDACs belonging to class I, cells were transfected with speciﬁc
siRNA for each of them: HDAC1, HDAC2, HDAC3 and HDAC8. As
seen in RT-PCR (Fig. 4A), all HDACs belonging to class I were
downregulated from 50% to 80% due to the speciﬁc siRNA effect. In
addition, no effect on the other class I HDAC level was highlighted
in HDAC1 siRNA transfected cells (data not shown).pression. (A) Relative quantiﬁcation of mRNA expression levels in PASMCs after 48 h
e expressed as mean  sem; *p < 0.05, **p < 0.01. (B) Effect of 48 h exposure to HDAC
d CycD1 levels increase after a 7-h treatment in PASMC. Total Akt and Vinculin were the
ve images of 3 different experiments. (C) Effect on phosphorylated Akt as assessed by a
al Akt level change compared to that of the scramble control. Relative quantiﬁcation of
 densitometric analysis of Western blot experiments. Results were expressed as CycD1/
tiﬁcation was shown as mean  sem; *p < 0.05, **p < 0.01. (E) Effect of siRNA against
f treatment. Data compared to the scramble + PDGF were expressed as mean  sem;
asured as the difference in cells covered area after 6 h of observation. Data compared to
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downregulation of Akt phosphorylation, only HDAC1 and HDAC2
siRNA signiﬁcantly reduced PDGF stimulation, while HDAC3 and
HDAC8 siRNA had no appreciable effect when compared to
scramble with addition of PDGF (Fig. 4B and C). Moreover, only
HDAC1 siRNA reduced signiﬁcantly PDGF-induced CycD1 protein
expression (Fig. 4B and D). Interestingly, both HDAC1 and HDAC2
silencing caused reduction of proliferation (Fig. 4E) and migration
(Fig. 4F) after 24 h and 6 h of treatment with PDGF, respectively.
3.5. A selective HDAC1 inhibitor efﬁciently mimics the effect of
MC1855 on proliferation and migration
To further demonstrate that HDAC1 was the key effector of
HDACi on PASMCs migration and proliferation, HDAC1-I, a
commercial HDAC1 speciﬁc inhibitor [27,28] was utilized.
Starved cells were treated with PDGF in the presence or absence
of 5 mM MC1855 or HDAC1-I at different concentrations ranging
from 0.2 to 50 mM.
As shown in Fig. 5, HDAC1-I reduced PASMC proliferation,
measured by MTT assay, in a dose-dependent manner from 2 toFig. 5. Effect of HDAC1 speciﬁc inhibitor (HDAC1-I) on PDGF-induced proliferation. (A) D
assay after 24 h. (B) Percentage of cells expressing proliferation marker ki67. The qua
independent experiments *p < 0.05; **p < 0.01; ***p < 0.005 vs PDGF-treated group. (C) Repre
used to assess total cell number. (For interpretation of the references to color in this ﬁgur50 mM without reducing the number of plated cells (Fig. 5A).
Remarkably, HDAC1-I showed a similar effect on proliferation
when used at the same concentration (5 mM) of MC1855 (Fig. 5A).
A matching effect on cell proliferation was also observed using
immunoﬂuorescence for ki67, a well-known marker of cycling
cells (Fig. 5B and C).
Argyrophilic nucleolar organizer region (AgNORs) morpho-
metric analysis showed that ribosomal biogenesis (mean na/Na
ratio) was signiﬁcantly increased in PASMCs after PDGF
stimulation; on the contrary, after HDACi treatment, it decreased
and became comparable to that seen in control cells (Fig. 6A and
B). A concomitant TUNEL assay showed that apoptosis was
not triggered by PDGF PASMCs stimulation with or without
HDACis treatment compared to control quiescent cells (data not
shown).
Likewise MC1855, wound healing assay showed that HDAC1-I
reduced in a dose dependent manner PDGF-induced migration in
PAH-PASMCs (Fig. 6C).
Similarly to MC1855 and to HDAC1 siRNA, after a 7-h treatment
HDAC1-I had a signiﬁcant effect on reduction of Akt phosphor-
ylation (Fig. 7A).ifferent doses of HDAC1-I effects on PDGF-induced proliferation evaluated by MTT
ntitative results are expressed as mean  sem and represent data averaged from 5
sentative images of ki67 immunostaining (red). Nuclear labeling with DAPI (blue) were
e legend, the reader is referred to the web version of this article.)
Fig. 6. Effect of HDAC1 speciﬁc inhibitor (HDAC1-I) on PDGF-induced PASMC proliferation and migration. (A) Representative images of silver-stained NOR proteins results.
Scale bars: 50 mm. (B) Morphometric analysis of silver-stained NOR proteins. Results were expressed as mean nucleolar/nuclear areas (m na/m Na) ratio normalized to
control. ***p < 0.005. (C) Effect of different doses of HDAC1-I on PDGF-induced migration extent, measured as the difference in cells covered area after 6 h of observation.
Results from 4 different experiments are expressed as mean  sem *p < 0.05; **p < 0.01; ***p < 0.005 vs PDGF treated group.
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expression at both protein (Fig. 7A and B) and RNA (Fig. 7C) level
with a stronger effect than MC1855.
4. Discussion
There is consensus evidence that an overexpression of HDACs
can cause epigenetic alterations associated with malignant cell
behavior, as shown by the correlation between the occurrence of
many cancers and genome-wide histone hypoacetylation [29].
Very recently, Zhao et al. [11] described changes in the expression
of HDAC proteins, speciﬁcally an increase in HDAC1 (class I) and
HDAC5 (class II), in human IPAH lungs. Therefore, not only all
cancer patients, but also PAH patients could potentially beneﬁt
from an epigenetic therapy.
We have previously tested the ability of NaBU and trichostatin
A (TSA), two broad-spectrum HDACis, to counteract PDGF in
inducing the proliferation of PASMCs isolated from PAH-rats [20].
Here, PASMC exposure to MC1855 and MC1575 was exploited
to take a glimpse on the action of HDAC class I and/or II,
respectively, in our experimental model. Naldi et al. [21]
previously, demonstrated that MC1855 has an inhibitory proﬁle
similar to that of MS-275 (Entinostat), a class I HDACi [30–33],
affecting hyperacetylation of all histones in HT29 colon cancer cells
more potently and with lower toxicity than suberoylanilide
hydroxamic acid (SAHA) a non-selective HDACi. Although the
newly designed synthetic inhibitor of class II HDACs MC1575
showed to be less potent in inhibiting HDACs than pan-inhibitor
TSA, it blocked dose-dependently the proliferation and induced
cell cycle arrest in ERa-positive MCF-7 breast cancer cells [8] and
melanoma cells [34].Here, we show that MC1855 dose- and time-dependently
inhibited proliferation and migration induced by PDGF in PASMCs
isolated from PAH-rats, as well as PDGF-induced vessel sprouting
from the pulmonary artery of PAH animals. The possibility that
MC1855 may have acted only on class I HDAC is strongly supported
by the observation that (i) the class II inhibitor MC1575 only blocked
the proliferative effect of the growth factor at a concentration at
which it has been shown to lack speciﬁcity for class II HDAC, also
acting on class I HDAC [8], and (ii) in contrast to MC1855, MC1575
had no effect on PDGF-induced migration in PAH-PASMCs and
PDGF-induced sprouting in pulmonary artery of PAH animals.
Time-course analysis of Akt phosphorylation and the results
yielded in the presence of the phosphatase inhibitor CA strongly
suggest that phosphatase-mediated dephosphorylation of Akt may
be a major underlying mechanism of HDACi action [20].
To this end, mimicking a pan-HDACi, MC1855 decreased Akt
phosphorylation at Ser473 induced by PDGF only after 7 h of
treatment. In agreement with our previous data, these results
suggest that HDAC inhibition may have blocked HDAC–phospha-
tase interaction(s), thus promoting the release of the phosphatase
and its subsequent association with Akt. This hypothesis is
consonant with the observation that in human glioblastoma cells
HDACis can interrupt Protein Phosphatase 1 (PP1) coupling with
HDAC1/HDAC6, promoting PP1/Akt assembly which leads to
inhibition of kinase activity [22]. Akin to this picture, Akt
deacetylation has been found to boost its phosphorylation and
activation [16].
Moreover, here we demonstrated that MC1855 reduced CycD1
expression at gene and protein level. The ability of the phosphatase
inhibitor CA to rescue CycD1 level suggested that Akt dephos-
phorylation induced by NaBU and by the class I speciﬁc HDACi is
Fig. 7. Effect of HDAC1 speciﬁc inhibitor (HDAC1-I) on Akt phosphorylation and CycD1 expression. (A) Phosphorylation state of Ser473-Akt and CycD1 protein level in PASMCs
after a 7 h treatment with PDGF with or without 5 mM MC1855, 5 mM HDAC1-I. Untreated cells were used as a control (Ctrl). Representative images of 5 different
experiments. (B) Effect on CycD1 level as assessed by a densitometric analysis of Western blot experiments. Results were expressed as CycD1/Vinculin level change compared
to that of the PDGF alone. Relative protein level quantiﬁcation was shown as mean  sem **p < 0.01; ***p < 0.005 vs PDGF treated group. (C) Transcriptional level of CycD1 in
PASMCs after 7 h PDGF-treatment with or without 5 mM HDAC1-I. Real-time PCR data, normalized to gapdh and actin b housekeeping genes, were expressed as relative fold change
of PDGF + HDACi compared to PDGF alone. Results of 3 different experiments were analyzed using REST 2009 software (QIAGEN): *p < 0.05.
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(phosphorylated) protein involved in positive regulation of cell
cycle.
On the contrary, the inhibition of class II HDACs failed to affect
either the phosphorylation state of Akt or CycD1 level, further
supporting a major involvement of class I HDACs in PDGF-induced
PASMC proliferation.
Additional information on the mechanism(s) by which different
HDACs belonging class I may regulate Akt phosphorylation have
been obtained by transducing PASMCs with siRNA speciﬁc for each
of the class I members: HDAC1, HDAC2, HDAC3 and HDAC8. Our
data showed that at 7 h, a time point at which MC1855 elicited a
signiﬁcant downregulation of phosphorylated Akt, only HDAC1
and HDAC2 siRNA signiﬁcantly reduced PDGF-induced Akt
stimulation. Interestingly, siRNA against HDAC1 and HDAC2
reduced both proliferation and migration induced by PDGF
treatment. However, HDAC1 siRNA reduced signiﬁcantly CycD1
protein expression, highlighting the prominent role of HDAC1 in
PASMC proliferation induced by PDGF. This ﬁnding is consistent
whit HDAC1 overexpression previously detected in lungs from
both IPAH patients and pulmonary hypertensive rats [11].
Further cue on the mechanisms underlying the action of
MC1855 can be inferred by the results yielded in the presence of
HDAC1-I, a commercially available HDAC1 speciﬁc inhibitor
[27,28]. Remarkably, MC1855 proved to act with a similar proﬁle
to, and at the same concentration of HDAC1-I, in affecting both
proliferation and migration of PASMCs.
So far, a major limitation in the therapeutic exploitation of
HDACi has emerged from the conﬂicting results yielded by the
merging of opposite effects elicited by inhibiting different isoforms
of different classes at the same time [35]. The present ﬁndings
highlight a selective involvement of HDAC1 within the class I ofHDACs in driving a number of crucial signaling events behind the
PDGF induced patterning in PAH PASMCs. Accordingly, the
development of novel inhibitors selectively targeted against class
I HDAC1 should be envisioned as a potentially effective tool to
handle the dysfunctional behavior of PASMCs in PAH. Further
studies are in progress to address this issue in in vivo PAH models.
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